<DOC>
	<DOCNO>NCT00002818</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Deoxycytidine may protect patient side effect high-dose cytarabine . PURPOSE : Phase I trial study effectiveness high-dose cytarabine give deoxycytidine treat patient refractory acute myelogenous leukemia lymphoma leukemia .</brief_summary>
	<brief_title>High-Dose Cytarabine Plus Deoxycytidine Treating With Acute Myelogenous Leukemia Other Hematologic Malignancies</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate low dose deoxycytidine ( dC ) give host protective agent conjunction high dose cytarabine ( HD ARA-C ) patient refractory acute myelogenous leukemia hematologic malignancy . II . Determine maximum tolerate dose dose-limiting toxic effect HD ARA-C/dC patient . III . Characterize pharmacokinetics continuously administer HD ARA-C/dC patient . IV . Characterize , possible , pharmacodynamics HD ARA-C , dC , metabolites blast obtain leukemic patient participate trial . V. Recommend low possible dose dC give combination HD ARA-C future phase II trial . OUTLINE : This dose escalation study . Patients receive deoxycytidine IV 120 hour . Beginning 12 hour initiation deoxycytidine , patient receive high dose cytarabine IV 96 hour . Patients achieve complete response receive therapy . Patients achieve partial response initial complete response subsequent relapse receive additional course therapy . Cohorts 3-6 patient receive escalate dos deoxycytidine high dose cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 24-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically document hematologic malignancy : Acute myelogenous leukemia Failed relapse follow conventional dose chemotherapy ( e.g. , doxorubicin , cytarabine ) high dose cytarabine ( HD ARAC ) Chronic myelogenous leukemia blast crisis fail least 1 conventional antileukemic regimen Acute lymphoblastic leukemia ( ALL ) relapse follow initially refractory conventional therapy Failed least 1 salvage regimen ALL Disease refractory conventional HD ARAC allow Primarily refractory relapse Hodgkin 's nonHodgkin 's lymphoma Failed least 1 conventional second third generation regimen ( e.g. , ProMACECytaBOM ) Refractory multiple myeloma Not eligible protocol high priority alternative form therapy available offer reasonable chance palliation cure PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : At least 8 week Hematopoietic : Not specify Hepatic : Bilirubin le 3 mg/dL Renal : Creatinine clearance least 40 mL/min Pulmonary : Pulse oximetry great 88 % patient history pulmonary disease Other : No major concurrent disease render patient poor medical risk No uncontrolled infection Disease relate fever allow investigator 's discretion No mental incapacity precludes inform consent No incarcerate patient Not pregnant Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : Not specify Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 24 hour since hydroxyurea ) recover Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 30 % bone marrow At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>